{"created":"2023-05-15T14:36:03.533348+00:00","id":46410,"links":{},"metadata":{"_buckets":{"deposit":"f5fd1204-3dbc-43ae-b851-1e0107277c11"},"_deposit":{"created_by":1,"id":"46410","owners":[1],"pid":{"revision_id":0,"type":"depid","value":"46410"},"status":"published"},"_oai":{"id":"oai:repo.qst.go.jp:00046410","sets":["1"]},"author_link":["462308","462309","462311","462317","462314","462316","462312","462313","462315","462310"],"item_8_biblio_info_7":{"attribute_name":"書誌情報","attribute_value_mlt":[{"bibliographicIssueDates":{"bibliographicIssueDate":"2011-01","bibliographicIssueDateType":"Issued"},"bibliographicIssueNumber":"1","bibliographicPageEnd":"28","bibliographicPageStart":"21","bibliographicVolumeNumber":"2","bibliographic_titles":[{"bibliographic_title":"Oncology Letters"}]}]},"item_8_description_5":{"attribute_name":"抄録","attribute_value_mlt":[{"subitem_description":"This study aimed to investigate whether glucose transporter-1 (GLUT-1) expression in a pretreatment esophageal cancer biopsy was predictive of clinical outcomes in patients with esophageal cancer undergoing concurrent chemoradiotherapy (CRT). A total of 25 patients with esophageal cancer treated with concurrent CRT were reviewed. Radiotherapy was administered up to total doses of 40-66.6 Gy (median 66.6 Gy) with a single fraction of 1.8-2 Gy. Regarding chemotherapy, cisplatin (80 mg/m2 on day 1) and 5-fluorouracil (800 mg/m2 on days 2-6) were used concurrently with radiotherapy, every 3-4 weeks for a total of 1-2 courses. Tissue samples from esophageal carcinoma were obtained from the 25 patients by biopsy prior to concurrent CRT, and a semiquantitative analysis of GLUT-1 expression was performed using immunohistochemical staining. High GLUT-1 expression was observed in 7 of 25 (28%) patients, and GLUT-1 expression was significantly correlated with clinical T stage (p=0.0454), clinical N stage (p=0.0324) and initial response to CRT (p=0.0185). Patients with a high GLUT-1 expression had significantly poorer local control (LC) (5-year LC 28.6%) than those with a low expression (5-year LC 73.4%, p<005). Multivariate analysis revealed that GLUT-1 and the number of chemotherapy courses were independent prognostic factors for LC. Patients with a high GLUT-1 expression had significantly lower recurrence-free survival (RFS) compared to those with a low GLUT-1 expression (p=0.0405). Multivariate analysis revealed that GLUT-1, the number of chemotherapy courses and clinical M stage were independent prognostic factors for RFS. GLUT-1 expression was significantly correlated with clinical T stage, clinical N stage and initial response to concurrentCRT, and was predictive of LC and RFS for patients with esophageal cancer treated with concurrent CRT.","subitem_description_type":"Abstract"}]},"item_8_relation_14":{"attribute_name":"DOI","attribute_value_mlt":[{"subitem_relation_type_id":{"subitem_relation_type_id_text":"10.3892/ol.2010.199","subitem_relation_type_select":"DOI"}}]},"item_8_source_id_9":{"attribute_name":"ISSN","attribute_value_mlt":[{"subitem_source_identifier":"1792-1074","subitem_source_identifier_type":"ISSN"}]},"item_access_right":{"attribute_name":"アクセス権","attribute_value_mlt":[{"subitem_access_right":"metadata only access","subitem_access_right_uri":"http://purl.org/coar/access_right/c_14cb"}]},"item_creator":{"attribute_name":"著者","attribute_type":"creator","attribute_value_mlt":[{"creatorNames":[{"creatorName":"Chiba, Itaru"}],"nameIdentifiers":[{"nameIdentifier":"462308","nameIdentifierScheme":"WEKO"}]},{"creatorNames":[{"creatorName":"Ogawa, Kazuhiko"}],"nameIdentifiers":[{"nameIdentifier":"462309","nameIdentifierScheme":"WEKO"}]},{"creatorNames":[{"creatorName":"Morioka, Takamitsu"}],"nameIdentifiers":[{"nameIdentifier":"462310","nameIdentifierScheme":"WEKO"}]},{"creatorNames":[{"creatorName":"Shimoji, Hideaki"}],"nameIdentifiers":[{"nameIdentifier":"462311","nameIdentifierScheme":"WEKO"}]},{"creatorNames":[{"creatorName":"Sunagawa, Nao"}],"nameIdentifiers":[{"nameIdentifier":"462312","nameIdentifierScheme":"WEKO"}]},{"creatorNames":[{"creatorName":"Iraha, Shiro"}],"nameIdentifiers":[{"nameIdentifier":"462313","nameIdentifierScheme":"WEKO"}]},{"creatorNames":[{"creatorName":"Nishimaki, Tadashi"}],"nameIdentifiers":[{"nameIdentifier":"462314","nameIdentifierScheme":"WEKO"}]},{"creatorNames":[{"creatorName":"Yoshimi, Naoki"}],"nameIdentifiers":[{"nameIdentifier":"462315","nameIdentifierScheme":"WEKO"}]},{"creatorNames":[{"creatorName":"Murayama, Sadayuki"}],"nameIdentifiers":[{"nameIdentifier":"462316","nameIdentifierScheme":"WEKO"}]},{"creatorNames":[{"creatorName":"森岡 孝満","creatorNameLang":"en"}],"nameIdentifiers":[{"nameIdentifier":"462317","nameIdentifierScheme":"WEKO"}]}]},"item_language":{"attribute_name":"言語","attribute_value_mlt":[{"subitem_language":"eng"}]},"item_resource_type":{"attribute_name":"資源タイプ","attribute_value_mlt":[{"resourcetype":"journal article","resourceuri":"http://purl.org/coar/resource_type/c_6501"}]},"item_title":"Clinical significance of GLUT-1 expression in patients with esophageal cancer treated with concurrent chemoradiotherapy","item_titles":{"attribute_name":"タイトル","attribute_value_mlt":[{"subitem_title":"Clinical significance of GLUT-1 expression in patients with esophageal cancer treated with concurrent chemoradiotherapy"}]},"item_type_id":"8","owner":"1","path":["1"],"pubdate":{"attribute_name":"公開日","attribute_value":"2012-10-02"},"publish_date":"2012-10-02","publish_status":"0","recid":"46410","relation_version_is_last":true,"title":["Clinical significance of GLUT-1 expression in patients with esophageal cancer treated with concurrent chemoradiotherapy"],"weko_creator_id":"1","weko_shared_id":-1},"updated":"2023-05-15T23:52:09.353619+00:00"}